An Open-label, Multicenter, Phase 1/1b Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination With Rituximab, or Obinutuzumab, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2017
At a glance
- Drugs DCDS 0780A (Primary) ; Obinutuzumab; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 12 Dec 2017 Results (n=48; As of May 31, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 24 Oct 2017 Planned End Date changed from 30 Sep 2019 to 4 Sep 2019.
- 24 Oct 2017 Planned primary completion date changed from 30 Sep 2019 to 4 Sep 2019.